MOBILE, AL – Gulf Coast BioSciences unveiled its CardioDetect™ platform today, a breakthrough rapid diagnostic system capable of identifying early-stage cardiovascular disease within 15 minutes from a single blood sample. The non-invasive technology addresses a critical gap in preventive cardiology by detecting biomarkers associated with coronary artery disease, heart failure, and stroke risk before symptoms emerge. The platform utilizes advanced microfluidic technology and artificial intelligence algorithms to analyze multiple cardiac biomarkers simultaneously, providing clinicians with actionable risk stratification data. Clinical validation studies demonstrate 94 percent sensitivity and 91 percent specificity across diverse patient populations. "CardioDetect™ represents a fundamental shift in how we approach cardiovascular disease prevention," said Dr. James R. Mitchell, Chief Medical Officer at Gulf Coast BioSciences. "By enabling early detection in primary care settings, we're empowering physicians to intervene before disease progression, ultimately saving lives and reducing healthcare costs." The platform requires minimal infrastructure, operates on existing laboratory equipment, and integrates seamlessly with electronic health records systems. Initial deployment will target cardiology practices, internal medicine clinics, and urgent care facilities across the Southeast, with national expansion planned for 2025. Gulf Coast BioSciences has secured $18 million in Series B funding to support regulatory submissions and commercial rollout. The CardioDetect™ platform is currently undergoing FDA review for clearance. **About Gulf Coast BioSciences** Founded in 2019, Gulf Coast BioSciences develops innovative diagnostic technologies addressing critical unmet needs in cardiovascular and metabolic disease detection. Headquartered in Mobile, Alabama, the company combines biomedical engineering expertise with clinical research to advance precision medicine solutions.